ProQR Therapeutics N.V (PRQR) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $0.12.
- ProQR Therapeutics N.V's EPS (Weighted Average and Diluted) rose 6.45% to $0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.71, marking a year-over-year decrease of 1.97%. This contributed to the annual value of -$0.34 for FY2024, which is 9.68% up from last year.
- Latest data reveals that ProQR Therapeutics N.V reported EPS (Weighted Average and Diluted) of $0.12 as of Q3 2025, which was up 186.06% from -$0.14 recorded in Q2 2025.
- ProQR Therapeutics N.V's EPS (Weighted Average and Diluted)'s 5-year high stood at $0.33 during Q3 2022, with a 5-year trough of -$1.65 in Q4 2022.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.03 (2024), whereas its average is -$0.10.
- In the last 5 years, ProQR Therapeutics N.V's EPS (Weighted Average and Diluted) crashed by 655.69% in 2022 and then skyrocketed by 58.99% in 2023.
- Quarterly analysis of 5 years shows ProQR Therapeutics N.V's EPS (Weighted Average and Diluted) stood at $0.30 in 2021, then tumbled by 655.69% to -$1.65 in 2022, then soared by 58.99% to -$0.68 in 2023, then rose by 13.29% to -$0.59 in 2024, then grew by 6.45% to $0.12 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.12 in Q3 2025, compared to -$0.14 in Q2 2025 and -$0.11 in Q1 2025.